Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA is investigating the risk of new lymphoma among patients receiving the engineered T cells, but so far, cases are rare.
The program will pay 65% of the cost of providing the custom-made immunotherapy.
After his first bout with acute lymphoblastic leukemia, Connor McMahon wanted to give other children hope.
We asked the experts what they think will be the next big breakthroughs.
The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.
About 80 percent of responders remained relapse-free a year after receiving tisagenlecleucel.
The overall response rate was 50%, with a complete response rate of 32%.
The custom immunotherapy is now indicated for adults with relapsed or refractory lymphoma.
Coming up at AACR: Chemotherapy can compromise CAR-T therapy and HER2 mutations may confer resistance to hormone therapy.
Cancer progress report highlights life-saving potential of immunotherapy, critical role of federal funding.
This approach has the potential to challenge the way cancer research is usually now done, one body part at a time.
Immunotherapy gives people with advanced lymphoma another treatment option.
Cutting-edge approach creates customized therapy.
Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.